Background
==========

Mutations in the lecithin:cholesterol acyltransferase (*LCAT*) gene cause either familial lecithin:cholesterol acyltransferase deficiency (FLD) (OMIM\# 245900) or fish-eye disease (FED, OMIM\# 136120) \[[@bib1]\]. FLD patients are characterized by a significant reduction in serum high-density lipoprotein cholesterol (HDL-C) level, corneal opacity, normochromic anemia and proteinuria with progression to end-stage renal disease \[[@bib1], [@bib2]\]. Plasma low-density lipoprotein cholesterol (LDL-C) levels are widely variable among FLD patients although plasma *LCAT* activity catalyzing HDL (*LCAT*α activity) and catalyzing apolipoprotein B containing lipoproteins (*LCAT*β activity) is absent or nearly absent. The loss of *LCAT* activity leads to increased levels of phosphatidylcholine and free cholesterol (FC) in the blood and to the formation of an abnormal lipoprotein called lipoprotein-X (Lp-X). As a result, accumulation of FC occurs in various tissues, including the cornea, erythrocyte membrane and the kidney \[[@bib3]\]. Recent report suggests an etiological role for Lp-X in the development of glomerulosclerosis \[[@bib4]\].

Here, we describe two novel mutations of *LCAT* gene, a C to T transition in Exon 2 converting proline 69 to leucine (Pro69Leu) and a T to C transition in Exon 6 converting methionine 293 to threonine (Met293Thr). Since Baass *et al.* \[[@bib5]\] hypothesized that the presence of the *APOE* ε2 allele contributed to the accumulation of intermediate-density lipoprotein (IDL) in the patients with *LCAT* deficiency, we investigated their *APOE* genotypes and phenotypic manifestations of the patients with FLD.

Case reports
============

Case presentation
-----------------

### Case 1.

A 27-year-old Japanese man was referred to Okayama University Hospital because he had extremely low HDL-C and LDL-C concentrations. On physical examination, he showed bilateral corneal opacity, but no other abnormal findings. Laboratory findings demonstrated a mild degree of normochoromic-normocytotic anemia (11.3 g/dL). Although his renal function was normal, (+1) proteinuria was revealed via the dipstick method (0.21 g/day). The consanguinity was found in his parents as shown in [Figure 1A](#fig1){ref-type="fig"}.

![Presented cases with FLD. (**A**, **B**) Family trees of Cases 1 and 2. Squares are male, circles are female. Filled symbols indicate homozygous carriers and left filled symbols indicate heterozygous carriers. The deceased subjects are indicated with the oblique lines. Members without genetic analysis are presented in gray tone. The consanguinity of patients\' parents are indicated by doubled line. (**C**, **D**) Determination of the *LCAT* gene sequences of proband and their families. Heterozygous mutation of mother and elder sister and homozygous mutation of proband are shown in Cases 1 (C) and 2 (D). (**E**, **F**) Renal biopsy findings of Cases 1 and 2. Electron micrograph shows lipid deposits with a vacuolar lucent appearance in the GBM (bar = 2 μm). (**G**--**I**) High-performance liquid chromatography patterns of Cases 1 (G), 2 (H) and normal healthy control (I).](ndtplussfr091f01_3c){#fig1}

### Case 2.

A 30-year-old Japanese woman was referred because of very low HDL-C and LDL-C associated with (1+) proteinuria via dipstick (0.08 g/day). She also showed bilateral corneal opacity and mild hemolytic anemia (11.2 g/dL), demonstrating target cells on her peripheral blood smear. Her renal function was within normal range. She was a daughter of consanguineous parents ([Figure 1B](#fig1){ref-type="fig"}).

Sequencing of LCAT gene, renal biopsy findings and LCAT activity
----------------------------------------------------------------

Direct sequencing of *LCAT* gene and comparison with reference sequence (NM_000229) revealed that Case 1 had a C to T nucleotide substitution in Exon 2 resulting in Pro69Leu \[c.278 C\>T (p.Pro69Leu)\] ([Figure 1C](#fig1){ref-type="fig"}) and Case 2 had a T to C substitution in Exon 6 resulting in Met293Thr mutations \[c.950 T\>C (p.Met293Thr)\] ([Figure 1D](#fig1){ref-type="fig"}). Both cases showed homozygous mutation and their parents showed heterozygous mutation. We further examined the *APOE* genotype of the presented cases. Case 1 carried *APOE* ε4/ε3 genotype, whereas Case 2 carried *APOE* ε2/ε2 genotype ([Table 1](#tbl1){ref-type="table"}). The mother of Case 1 carried *APOE* ε3/ε3 genotype and genomic DNAs were not available from the deceased father. The parents of Case 2 carried *APOE* ε3/ε2 genotype. Renal biopsy in both cases revealed similar histological findings; diffuse vacuolization of the glomerular basement membranes (GBM) by periodic acid-methenamine silver stain and lipid deposits with a vacuolar lucent appearance in the mesangial matrix and the GBM by electron microscopy ([Figure 1E and F](#fig1){ref-type="fig"}). In both cases, half normal *LCAT* activity was observed by using exogenous substrate, suggesting the diagnosis of FED. However, clinical manifestations with hemolytic anemia and renal involvement coincided with the features of FLD.

###### 

Characteristics and lipoprotein profiles of presented cases[a](#tblfn1){ref-type="table-fn"}

                                                      Normal values   Case 1       Case 2         Mother of Case 2
  --------------------------------------------------- --------------- ------------ -------------- ------------------
  Sex                                                                 Male         Female         Female
  Age (years)                                                         27           30             55
  c.278 C\>T (p.Pro69Leu)                                             Homozygous   none           none
  c.950 T\>C (p.Met293Thr)                                            none         Heterozygous   Heterozygous
  Total cholesterol (mg/dL)                           130--220        84           73             193
  Triglycerides (mg/dL)                               40--150         90           71             97
  LDL-cholesterol (mg/dL) (direct homogenous assay)   70--139         28           24             126
  HDL-cholesterol (mg/dL)                             41--85          3            5              43
  FC (mg/dL)                                          25--60          61           50             55
  Cholesteryl ester (mg/dL)                           90--200         23           23             138
  FC/TC (%)                                           \<28            72.6         68.5           28.4
  RemL-C (mg/dL)                                      0.0--7.5        34.4         23.2           5.4
  Phospholipid (mg/dL)                                150--250        157.8        178.3          ND
  Apo A-I (mg/dL)                                     119--155        46           69             124
  Apo A-II (mg/dL)                                    25.9--35.7      5.3          5.1            28.3
  Apo B (mg/dL)                                       73--109         60           40             113
  *LCAT* activity (nmol/mL/h/37°C)                    M 67.3--108.2   31.7         29.4           ND
  F 53.3--95.5                                                                                    
  *APOE* genotype                                                     ϵ4/ϵ3        ϵ2/ϵ2          ϵ3/ϵ2

RemL-C, remnant-like particles cholesterol measured with MetaboLead RemL-C; ND, not determined.

Plasma lipids and lipoproteins
------------------------------

Both Cases 1 and 2 revealed similar lipid profile; LDL-C and HDL-C were extremely low ([Table 1](#tbl1){ref-type="table"}). Furthermore, FC/total cholesterol (TC) ratio was much higher than normal value, suggesting reduced activity of esterification of plasma cholesterol due to *LCAT* deficiency. In both cases, the lipoproteins in fraction 7--10, corresponding to IDL particle size, were characterized by triglycerides (TG)- and phospholipid (PL)-rich. Since Lp-X is FC- and PL-rich lipoprotein particle, the peaks appeared in fraction 7--10 seem to be remnant lipoproteins containing IDL remnant ([Figure 1G and H](#fig1){ref-type="fig"}; arrows). In addition, Lp-X was not detected by agarose gel electrophoresis in both cases. The remnant-like particles cholesterol was measured with MetaboLead RemL-C well-reflects IDL remnant compared with immunoseparation assay, the high values of RemL-C in both cases also support the elevation of IDL remnant.

Discussion
==========

Lynn *et al.* \[[@bib6]\] recently reported that accumulation of Lp-X in renal lesion can stimulate monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-κB. Nishiwaki *et al.* \[[@bib7]\] reported Lp-X is larger than normal LDL-C in size, and the percentages for TG, cholesteryl ester, FC and PL were 9.5, 6.2, 27.6 and 56.8% in Lp-X, respectively. In our cases, we found TG- and PL-rich remnant IDL particles, where TC and FC contents are very low. Previous research has observed that *APOE* ε2 allele carriers reveal decreased LDL-C and increased TG and lipoprotein remnants, whereas *APOE* ε4 carriers have increased LDL-C and TG in comparison to ε3/ε3 subjects \[[@bib8], [@bib9]\]. It has been suggested that lipoproteins of ε2 carriers have a low affinity for lipoprotein receptors, which induces decreased cholesterol delivery to the hepatocytes and a following upregulation of hepatic sterol synthesis and LDL receptors \[[@bib10]\]. Therefore, a decreased conversion of very low-density lipoprotein into LDL and appearance of IDL is observed in ε2 carriers. Baass *et al.* \[[@bib5]\] hypothesized that the presence of the *APOE* ε2 allele contributed to the accumulation of IDL instead of Lp-X in the patients with *LCAT* deficiency, but IDL remnant is even higher in Case 1 carrying *APOE* ε4/ε3 genotype compared with Case 2 with *APOE* ε2/ε2 genotype ([Figure 1G and H](#fig1){ref-type="fig"}). The discrepancy of these observations may attribute to the difference in mutations of *LCAT* gene rather than *APOE* genotype and further characterization of enzymatic activities of mutated gene products is required in future investigations.

In conclusion, we describe two unrelated FLD patients with corneal opacity, hemolytic anemia, abnormalities in serum lipoprotein profile and lipid accumulation in GBM. Instead of Lp-X, we detected IDL remnant in both cases and similar pathological findings in renal biopsy. Genotyping *APOE* gene revealed *APOE* ε4/ε3 in Case 1 and a rare association of *APOE* ε2/ε2 in Case 2, thus *APOE* ε2/ε2 may not be the major modifier gene for the appearance of IDL in FLD patients. More cases need to be investigated to draw the definitive conclusions on the relation among *LCAT* mutation, *APOE* genotype and lipoprotein profile in FLD patients.
